Document Detail

Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients.
MedLine Citation:
PMID:  18191989     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate subclinical atherosclerosis and the effect of treatment in patients with early rheumatoid arthritis (RA). PATIENTS AND METHODS: Forty patients with early RA who met the revised American College of Rheumatology (ACR) criteria and disease duration of <1 year were included in the study. Smokers and patients with classical risk factors for atherosclerosis were excluded. The serum levels of total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol were determined in all patients before and after 1 year of therapy. Carotid artery intima-media thickness (IMT) and carotid plaque were measured before and after treatment. RA disease activity was measured using the 28 joint indices score (DAS-28) and clinical improvement was determined by the ACR response criteria. Forty-five age- and sex-matched nonsmoking volunteers were used as controls. All patients were treated with methotrexate and prednisone. RESULTS: RA patients had a baseline mild dyslipidemia characterized by a decrease in serum HDL-C levels and a high TC/HDL-C atherogenic ratio compared with controls. Both lipid parameters were significantly improved after treatment (P<0.01). Common carotid artery IMTs at baseline were higher in RA patients compared with controls (P<0.05). After 1 year of therapy there was a significant decrease in the IMTs (P<0.001). Thirty-five patients (88%) achieved the ACR 20%, while 30 (75%) reached the ACR 50% response criteria. A significant decrease of DAS-28 was observed after treatment (P<0.03). CONCLUSIONS: The atherogenic lipid profile and subclinical atherosclerosis are features of early RA, which improved after therapy. Early intervention and control of the disease activity may reduce the risk of atherosclerosis and cardiovascular events in patients with RA.
Athanasios N Georgiadis; Paraskevi V Voulgari; Maria I Argyropoulou; Yannis Alamanos; Moses Elisaf; Alexandros D Tselepis; Alexandros A Drosos
Related Documents :
9917959 - Pulmonary manifestations of rheumatoid arthritis.
20092399 - Increased expression of proto-oncogene survivin predicts joint destruction and persiste...
12180719 - Cardiovascular risk factors in chilean patients with rheumatoid arthritis.
3229079 - Evaluation of the renal injury from gold salts and nonsteroidal anti-inflammatory drugs...
12969349 - Vocal fold deposits in autoimmune disease--an unusual cause of hoarseness.
23018349 - Probing the use of fluorescence spectroscopy as a novel diagnostic tool in patients wit...
24796799 - Liver enzyme elevations within three months of diagnosis of inflammatory bowel disease ...
19787469 - The effects of cachexia and related components on pulmonary functions in patients with ...
18609069 - Accuracy of n-terminal-pro-atrial natriuretic peptide in patients admitted to emergency...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-01-14
Journal Detail:
Title:  Seminars in arthritis and rheumatism     Volume:  38     ISSN:  0049-0172     ISO Abbreviation:  Semin. Arthritis Rheum.     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-22     Completed Date:  2008-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1306053     Medline TA:  Semin Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  13-9     Citation Subset:  IM    
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / complications,  drug therapy*
Cardiovascular Diseases / complications*
Immunosuppressive Agents / therapeutic use*
Methotrexate / therapeutic use
Middle Aged
Prednisone / therapeutic use
Risk Factors
Reg. No./Substance:
0/Immunosuppressive Agents; 53-03-2/Prednisone; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trace element concentrations in blood of harbor seals (Phoca vitulina) from the Wadden Sea.
Next Document:  Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping co...